PRIVIGEN®

FDA INDICATION: Primary immunodeficiency disease (PIDD), idiopathic thrombocytopenic purpura (ITP), chronic inflammatory demyelinating polyneuropathy (CIDP) Package Insert

FORM: Liquid

DISTRIBUTOR: CSL Behring

ROUTE OF ADMINISTRATION: Intravenous

PH (AFTER RECONSTITUTION): 4.6–5

CONCENTRATION: 10%

IGA CONTENT: <25 μg/mL

% IGG: ≥98%

NA CONTENT: Trace amounts

DILUENT: N/A

OSMOLALITY (MOSM/L): 320

INITIAL INFUSION RATE: PIDD: Initial rate of 0.005 mL/kg/min. If tolerated, increase gradually to 0.08 mL/kg/min.
ITP: Initial rate of 0.005 mL/kg/min. If tolerated, increase gradually to 0.04 mL/kg/min.

SUGAR CONTENT: No added sugars

SHELF LIFE: 36 months

STORAGE REQUIREMENTS: Store at room temperature up to 25°C (77°F). Do not freeze. Protect from light.

FLUSHING COMPATIBILITY: Saline or dextrose

PATIENT SUPPORT/ASSISTANCE PROGRAMS: CSL Behring Patient Assistance Program, CSL Behring Assurance Program

OTHER WEBSITES: TreatingPI, privigen.com